Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes
Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes
Background: breast cancer has a significant heritable basis, of which ∼60% remains unexplained. Testing for BRCA1/BRCA2 offers useful discrimination of breast cancer risk within families, and identification of additional breast cancer susceptibility genes could offer clinical utility.
Patients and methods: we included 2135 invasive breast cancer cases recruited via the Breast and Ovarian Cancer Susceptibility study, a retrospective UK study of familial breast cancer. Eligibility criteria: female, BRCA-negative, white European ethnicity, and one of: (i) breast cancer family history, (ii) bilateral disease, (iii) young age of onset (<30 years), and (iv) concomitant ovarian cancer. We undertook exome sequencing of cases and carried out gene-level burden testing of rare damaging variants against those from 51 377 ethnicity-matched population controls from gnomAD.
Results: 159/2135 (7.4%) cases had a qualifying variant in an established breast cancer susceptibility gene, with minimal evidence of signal in other cancer susceptibility genes. Known breast cancer susceptibility genes PALB2, CHEK2, and ATM were the only genes to retain statistical significance after correcting for multiple testing. Due to the enrichment of hereditary cases in the series, we had good power (>80%) to detect a gene of BRCA1-like risk [odds ratio (OR) = 10.6] down to a population minor allele frequency of 4.6 × 10 −5 (1 in 10 799, less than one-tenth that of BRCA1)and of PALB2-like risk (OR = 5.0) down to a population minor allele frequency of 2.8 × 10 −4 (1 in 1779, less than half that of PALB2). Power was lower for identification of novel moderate penetrance genes (OR = 2-3) like CHEK2 and ATM.
Conclusions: this is the largest case-control whole-exome analysis of enriched breast cancer published to date. Whilst additional breast cancer susceptibility genes likely exist, those of high penetrance are likely to be of very low mutational frequency. Contention exists regarding the clinical utility of such genes.
Adult, Breast Neoplasms/genetics, Female, Genetic Predisposition to Disease, Germ-Line Mutation, Humans, Ovarian Neoplasms/genetics, Retrospective Studies, Triple Negative Breast Neoplasms
1318-1327
Loveday, C
bed064d6-13e9-4429-b847-5ecaaf3f5e19
Garrett, A
521fb99a-7bbc-4cd9-a9ad-9b5ba3a2b60a
Law, P
26c1c551-e8c5-439f-b65d-b2f4028e064a
Hanks, S
cf861ea5-cf32-43d5-93f2-1daa95ecc165
Poyastro-Pearson, E
e9274b75-f33b-45fa-bc9c-b005dbb20ea7
Adlard, J W
bcdaa0f7-cde2-412f-9702-4e6baf0ab0eb
Barwell, J
696ff7d9-e20d-4004-bf1c-5682ee7f5f19
Berg, J
2ba2b1b4-08a3-455b-b2b0-3c6f2d425f44
Brady, A F
9a5eebe7-772c-4642-be03-22e2d74fb266
Brewer, C
f50e5721-93d3-43ef-8cd2-572f238d04be
Chapman, C
8461c06e-9ef7-4835-ba4d-85f5da3165b3
Cook, J
52cb18f8-81e7-4ff6-952a-dfdbf1a95360
Davidson, R
4b0d9036-3fe0-42cb-8399-ffca5e6fdcb8
Donaldson, A
ea10ac5a-4f77-4ef5-91d5-7f32ea33db36
Douglas, F
9dc3db90-827e-419d-86f1-48e22b6845ab
Greenhalgh, L
3e8784cb-64e7-461c-b4a1-9f1dcdebf216
Henderson, A
4351cc44-7e50-4f5b-9073-0abe9e1b3aa3
Izatt, L
5cabcdef-374a-4441-b571-9c7b1665b720
Kumar, A
e22938e7-3688-4f13-9f13-00fa8de1e26f
Lalloo, F
60a2edba-59dd-4e37-9b3d-9eff7f8f7106
Miedzybrodzka, Z
88cf9144-bcf0-4490-a0e4-21d0df095155
Morrison, P J
b2d85956-d63c-4d00-b8ed-b821a43eae4f
Paterson, J
c8c5cee9-8345-4140-bd3e-9bc62186b2f2
Porteous, M
cfcccad0-0a90-4ec6-ab3f-ec60eaf9de33
Rogers, M T
926d58e9-580a-4ed7-9330-7ed87e89d252
Walker, L
4dbefefc-6a93-46f9-9070-4fa28733d6e4
Eccles, D
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Evans, D G
679575fd-0c1c-4bcc-a24f-d04ef10cf9c5
Snape, K
bfd0af55-1a6d-41d0-aad6-2b3b0b4c73e2
Hanson, H
49da4aa7-56f4-4a1e-bf11-203ac42a8b77
Houlston, R S
0292e06f-2fd2-4b71-a629-00b288016474
Turnbull, C
b24a936c-c216-44a3-83b8-1d1c54dfb1c6
Breast and Ovarian Cancer Susceptibility Collaboration
1 December 2022
Loveday, C
bed064d6-13e9-4429-b847-5ecaaf3f5e19
Garrett, A
521fb99a-7bbc-4cd9-a9ad-9b5ba3a2b60a
Law, P
26c1c551-e8c5-439f-b65d-b2f4028e064a
Hanks, S
cf861ea5-cf32-43d5-93f2-1daa95ecc165
Poyastro-Pearson, E
e9274b75-f33b-45fa-bc9c-b005dbb20ea7
Adlard, J W
bcdaa0f7-cde2-412f-9702-4e6baf0ab0eb
Barwell, J
696ff7d9-e20d-4004-bf1c-5682ee7f5f19
Berg, J
2ba2b1b4-08a3-455b-b2b0-3c6f2d425f44
Brady, A F
9a5eebe7-772c-4642-be03-22e2d74fb266
Brewer, C
f50e5721-93d3-43ef-8cd2-572f238d04be
Chapman, C
8461c06e-9ef7-4835-ba4d-85f5da3165b3
Cook, J
52cb18f8-81e7-4ff6-952a-dfdbf1a95360
Davidson, R
4b0d9036-3fe0-42cb-8399-ffca5e6fdcb8
Donaldson, A
ea10ac5a-4f77-4ef5-91d5-7f32ea33db36
Douglas, F
9dc3db90-827e-419d-86f1-48e22b6845ab
Greenhalgh, L
3e8784cb-64e7-461c-b4a1-9f1dcdebf216
Henderson, A
4351cc44-7e50-4f5b-9073-0abe9e1b3aa3
Izatt, L
5cabcdef-374a-4441-b571-9c7b1665b720
Kumar, A
e22938e7-3688-4f13-9f13-00fa8de1e26f
Lalloo, F
60a2edba-59dd-4e37-9b3d-9eff7f8f7106
Miedzybrodzka, Z
88cf9144-bcf0-4490-a0e4-21d0df095155
Morrison, P J
b2d85956-d63c-4d00-b8ed-b821a43eae4f
Paterson, J
c8c5cee9-8345-4140-bd3e-9bc62186b2f2
Porteous, M
cfcccad0-0a90-4ec6-ab3f-ec60eaf9de33
Rogers, M T
926d58e9-580a-4ed7-9330-7ed87e89d252
Walker, L
4dbefefc-6a93-46f9-9070-4fa28733d6e4
Eccles, D
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Evans, D G
679575fd-0c1c-4bcc-a24f-d04ef10cf9c5
Snape, K
bfd0af55-1a6d-41d0-aad6-2b3b0b4c73e2
Hanson, H
49da4aa7-56f4-4a1e-bf11-203ac42a8b77
Houlston, R S
0292e06f-2fd2-4b71-a629-00b288016474
Turnbull, C
b24a936c-c216-44a3-83b8-1d1c54dfb1c6